The Arrangement is subject to court, shareholder and customary regulatory approvals. It is expected that Chromos will hold a meeting of shareholders to consider the Arrangement on or about September 9, 2008, and if approved, that the Arrangement will be completed before the end of September 2008. It is expected that a management information circular relating to the Meeting, containing the terms of the Arrangement, will be mailed to Chromos' shareholders in the next few weeks.
Chromos also announced today that the TSX Venture Exchange has conditionally approved the listing of the common shares of Calyx, subject to the satisfaction of customary conditions. There can be no assurance that such shares will be listed on a stock exchange.
Certain statements in this news release may contain "forward-looking
statements" or "forward-looking information" within the meaning of
applicable securities legislation Often, but not always, forward-looking
statements or information can be identified by the use of words such as
"plans", "expects" or "does not expect", "is expected", "budget",
"scheduled", "estimates", "forecasts", "intends", "anticipates" or "does
not anticipate", or "believes" or variations of such words and phrases or
words and phrases that state or indicate that certain actions, events or
results "may", "could", "would", "might" or "will" be taken, occur or be
achieved. Such forward-looking statements or information include, without
limitation, statements or information about the timing and success of
application to obtain approvals required with respect to the Arrangement,
and the listing of the shares of Calyx Bio-Ventures Inc. With respect to
forward-looking statements and information contained herein, we have made
|SOURCE Chromos Molecular Systems Inc.|
Copyright©2008 PR Newswire.
All rights reserved